PRPO — Precipio Inc
NASDAQ · Healthcare · Diagnostics & Research
$27.20
-$0.57 (-2.03%)
Precipio Inc (PRPO) is a diagnostics & research company listed on NASDAQ. It is led by Ilan Danieli, based in 4 Science Park, New Haven, CT, United States, 06511, with about 61 employees. Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.
Latest reported PRPO revenue for 2025-09-30 was $6.8M. Net income was -$79.0K. Revenue was up 19.7% from 2025-06-30 to 2025-09-30. PRPO currently screens at market cap $39.0M.
Use this PRPO page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the PRPO quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the PRPO SEC filings page. Lician reads the product cache first so this HTML stays unique to Precipio Inc even when a live quote feed is slow.
About Precipio Inc
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.
PRPO Key Statistics
Market Cap
$39.02M
Volume
91,025
Previous Close
$30.85
Day Range
$29.57 – $32.57
P/B Ratio
2.81
EPS
-$2.93
Revenue
$18.53M
Net Income
-$4.29M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+21.9%
Profit Margin
-23.1%
Employees
61
PRPO Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $18.53M | $15.20M | $9.41M | $8.85M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$4.29M | -$5.85M | -$12.18M | -$8.52M |
| EPS (Diluted) | -$2.93 | -$4.51 | -$10.73 | -$0.40 |
Total Assets
$17.00M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$1.39M
Operating Cash Flow
$439.00K
Free Cash Flow
$0.00
Precipio Inc Company Information
- Founder, President, CEO & Director
- Ilan Danieli
- Headquarters
- 4 Science Park, New Haven, CT, United States, 06511
- Website
- www.precipiodx.com
- Phone
- 203 787 7888
- IPO / Founded
- 2000-07-18
- Sector
- Healthcare
- Industry
- Diagnostics & Research